Table 1.
Baseline demographics and procedural risk factors for patients undergoing ERCP with and without ampullary biopsy
| ERCP with biopsy (N = 54) | ERCP without biopsy (N = 54) | P value | |
|---|---|---|---|
| Female, n (%) | 22 (40.7) | 29 (53.7) | 0.24 |
| Mean age, years | 62.9 | 56.7 | 0.07 |
| Common bile duct size, mm | 8.3 ± 2.7 | 7.5 ± 2.4 | 0.12 |
| Trainee involvement, n (%) | 43 (79.6) | 39 (72.2) | 0.5 |
| Total bilirubin level, μmol/L | 2.7 ± 3.2 | 3.3 ± 2.6 | 0.28 |
| Normal bilirubin, n (%) | 18 (33.3) | 13 (24.1) | 0.4 |
| Pancreatic duct injection, n (%) | 6 (11.1) | 4 (7.4) | 0.74 |
| Pancreatic duct stent, n (%) | 3 (5.6) | 3 (5.6) | 1.0 |
| Major papilla sphincterotomy, n (%) | 34 (63.0) | 40 (74.1) | 0.9 |
| ASA class, n (%) | 0.9 | ||
| II | 7 (13.0) | 12 (22.2) | |
| III | 46 (85.2) | 40 (74.1) | |
| IV | 1 (1.9) | 2 (3.7) | |
| ASGE grade, n (%) | 0.99 | ||
| 1 | 31 (57.4) | 31 (57.4) | |
| 2 | 19 (35.2) | 19 (35.2) | |
| 3 | 4 (7.4) | 4 (7.4) | |
| Periprocedural antibiotic use, n (%) | 8 (14.8) | 11 (20.4) | 0.6 |
| Periprocedural antiplatelet use, n (%) | 4 (7.4) | 7 (13.0) | 0.5 |
ASA: American Society of Anesthesiologists; ASGE: American Society for Gastrointestinal Endoscopy; ERCP: endoscopic retrograde cholangiopancreatography.